In recent studies, it has been demonstrated that somatic mutations in Nrf2 and Keap1 are identified in some tumors such as lung, head, and neck tumors, resulting in sustained activation of Nrf2 and induction of Nrf2 target genes such as cytoprotective enzymes and antioxidant proteins that have the capacity for antioxidative stress and anti-cancer agents [9]. This evidence concerns the gene KEAP1 and cancer.